The purpose of the present study was to evaluate the prognostic values of questionnaires in patients with unilateral SSNHL and to identify clinical features of the non-recovery group after medical treatment/intervention.
Patients included in the study showed the following characteristics: (1) complained of unilateral acute hearing loss within 72 hours; (2) had been objectively diagnosed with SSNHL according to initial pure tone audiometry (PTA) (an increase of more than 30 dB in the hearing threshold over three consecutive frequencies); (3) complained of dizziness and/or ipsilateral tinnitus as accompanying symptoms; (4) answered questionnaires (DHI and/or THI) at the first visit; and (5) were followed up with PTA 3 months after treatment.
The chief issue raised by the present study is whether SSNHL has a relationship with tinnitus and dizziness.
SSNHL is a sudden and unexplained hearing loss for at least 30 dB, which is repeated during 3 consecutive hearing test, occurs in less than 72 hours, and is idiopathic in most cases.
The etiology of most sudden SSNHL cases is unknown.
Hence, children in very young age with a bilateral hearing loss should alert the occurrence of SSNHL.
The PLT results may justify further research into the use of thrombolytic drugs in children with SSNHL.
4) SSNHL can be viewed as a part which falls in a broader spectrum of disease like vestibule- cochlear dysfunction.
At the auditory end of the spectrum SSNHL fits in with only hearing loss with mild, brief and transient vertiginous symptom.
Of these 23 patients, 13 had BPSNHL, eight had UPSNHL, and two had SSNHL.
Of the 10 cyclophosphamide patients, six had BPSNHL, two had UPSNHL, and two had SSNHL.
CONCLUSIONS: Autoimmunity is recognized as an etiological factor in the causation of SSNHL